NCT00681343

Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Living Donor Renal Transplantation

Head-to-Head Comparison of Thymoglobulin vs. Campath-1H vs. Our Standard Center Treatment Protocol in Living Donor Renal Transplantation - A Study to Evaluate the Avoidance of Long-Term Nephrotoxic Calcineurin Inhibitor Therapy

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 38 (actual)
• Sponsor: University of Miami · Academic / Other
• Sex: All
• Age: 16 Years
• Healthy volunteers: Not accepted

Summary

To observe in a randomized prospective pilot study the effectiveness and toxicity of Thymoglobulin vs. Campath-1H used for induction therapy in recipients of living donor (LD) kidneys, compared with our standard treatment protocol of Zenapax® and maintenance immunosuppression

Conditions

• Living-Donor Kidney Transplant

Interventions

Type	Name	Description
DRUG	Thymoglobulin	Induction
DRUG	Campath-1H	Induction
DRUG	Daclizumab	Induction

Timeline

• Start date: 2002-09-01
• Primary completion: 2006-10-01
• Completion: 2007-10-01
• First posted: 2008-05-21
• Last updated: 2023-09-14

Locations

1 site across 1 country: United States